Clinical Trial Update: Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of Lmp1 and Lmp2-specific cytotoxic T lymphocytes following CD45 antibody for relapsed EBV-positive Hodgkin lymphoma or non-Hodgkin lymphoma has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Lmp1 and Lmp2-specific CTLs following CD45 antibody

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkins Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Status: TERMINATED